MLchartDataset catalogue

selective estrogen receptor covalent antagonist TQB3915

Term · Oncology and biomedicine · MLC-T-ONC-016667

An orally bioavailable, selective and covalent antagonist of estrogen receptor alpha (ERalpha; ERa; ESR1; nuclear receptor subfamily 3, group A, member 1; NR3A1), with potential antineoplastic activity. Upon oral administration, selective estrogen receptor covalent antagonist TQB3915 selectively and covalently binds to and inhibits the activity of ERalpha. This inhibits the growth and survival of ERalpha-expressing cancer cells. ERalpha, a nuclear hormone receptor often overexpressed and/or mutated in a variety of cancer cell types, plays a key role in tumor cell proliferation and survival.

Table 1. Record
IdentifierMLC-T-ONC-016667
FieldOncology and biomedicine
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-016667",
  "term": "selective estrogen receptor covalent antagonist TQB3915",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable, selective and covalent antagonist of estrogen receptor alpha (ERalpha; ERa; ESR1; nuclear receptor subfamily 3, group A, member 1; NR3A1), with potential antineoplastic activity. Upon oral administration, selective estrogen receptor covalent antagonist TQB3915 selectively and covalently binds to and inhibits the activity of ERalpha. This inhibits the growth and survival of ERalpha-expressing cancer cells. ERalpha, a nuclear hormone receptor often overexpressed and/or mutated in a variety of cancer cell types, plays a key role in tumor cell proliferation and survival.",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/selective-estrogen-receptor-covalent-antagonist-tqb3915/"
}

Record 14,798 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.